Latest news about Genpharmasec
Genpharmasec
1.18
+0.02(+1.72%)
Company Performance:
View Company Insights1D+1.72%
1M+12.38%
6M+5.36%
1Y-39.49%
5Y0.00%
More news about Genpharmasec
23May 26
Genpharmasec FY26 Net Profit Rises to ₹544.96 Lakh
Genpharmasec Limited reported a standalone net profit of ₹544.96 lakh for FY26, a significant rise from ₹280.04 lakh in the previous year, driven by a surge in revenue to ₹13,134.94 lakh. The consolidated net profit stood at ₹56.01 lakh. The Board approved the results on May 21, 2026, and the company published the audited financial results in newspapers on May 23, 2026.
13May 26
Genpharmasec Limited Schedules Board Meeting on May 21, 2026 to Approve FY26 Audited Financial Results
Genpharmasec Limited has notified BSE Limited of a Board of Directors meeting to be held on May 21, 2026, to consider and approve audited standalone and consolidated financial results for the quarter and year ended March 31, 2026. The intimation was filed under Regulation 29 read with Regulation 33 of SEBI (LODR) Regulations, 2015. The company has also enforced a trading window closure from April 1, 2026, until 48 hours after the declaration of results, applicable to all Directors, Designated Persons, their immediate relatives, and specified Connected Persons. The communication was digitally signed by Mr. Sohan Chaturvedi, Whole Time Director and CFO, on May 13, 2026.
14Apr 26
Genpharmasec Limited Declares Non-Applicability of Large Corporate Framework Under SEBI Regulations
Genpharmasec Limited has declared to BSE Limited that it does not qualify as a Large Corporate under SEBI regulations, specifically referencing circulars SEBI/HO/DDHS-RACPOD1/P/CIR/2023/172 and SEBI/HO/DDHS/CIR/P/2018/144. The declaration, made on April 14, 2026, by Whole Time Director and CFO Mr. Sohan Chaturvedi, exempts the company from disclosure obligations related to debt securities issuance frameworks applicable to Large Corporates.
08Apr 26
Genpharmasec Limited Submits SEBI Compliance Certificate for Q4 FY26
Genpharmasec Limited has submitted its quarterly compliance certificate under SEBI Regulation 74(5) for Q4 FY26 to BSE Limited. The certificate, issued by RTA Satellite Corporate Services Pvt. Ltd, confirms no physical share certificates were received for dematerialization during the quarter ended March 31, 2026. The filing was completed on April 8, 2026, by Whole Time Director and CFO Mr. Sohan Chaturvedi, demonstrating the company's adherence to regulatory compliance requirements.
24Mar 26
Genpharmasec Limited Conducts Independent Directors Meeting on March 24, 2026
Genpharmasec Limited held its mandatory separate meeting of independent directors on March 24, 2026, lasting 30 minutes from 11:00 A.M. to 11:30 A.M. The meeting addressed three key governance areas: reviewing performance of non-independent directors and the board, assessing the chairperson's performance with input from executive and non-executive directors, and evaluating information flow quality between management and the board. The session was conducted in compliance with Companies Act 2013 and SEBI LODR Regulations 2015, with the outcome officially communicated to BSE Limited through proper documentation signed by Independent Director Mr. Siddhesh Shende.
09Feb 26
Genpharmasec Limited Reports Q3FY26 Results with Strong Standalone Revenue Growth
Genpharmasec Limited reported Q3FY26 financial results showing strong standalone revenue growth of 332% to Rs. 3,600.83 lakhs, driven by operational expansion. However, profit margins compressed due to increased material costs, while consolidated operations faced integration challenges from the recent Derren Healthcare acquisition, resulting in consolidated losses despite revenue growth.
07Aug 25
Genpharmasec Limited Reports Strong Q1 Results with 128% Revenue Growth
Genpharmasec Limited announced robust Q1 FY24 results. Consolidated revenue grew 132% to Rs 1,204.32 lakh, while profit surged 324% to Rs 121.52 lakh. Standalone revenue increased 128% to Rs 1,211.32 lakh, with profit up 165% to Rs 155.92 lakh. The pharmaceutical segment remained the primary revenue driver, contributing Rs 1,167.09 lakh. The company's Board approved these results on August 7, and confirmed no deviation in the use of proceeds from its rights issue.
25Jul 25
Genpharmasec Completes 70% Acquisition of Derren Healthcare for INR 34.15 Crores
Genpharmasec Limited has acquired a 70% stake in Derren Healthcare Private Limited for INR 34.15 crores. The acquisition, completed on July 25, 2025, marks Genpharmasec's entry into pharmaceutical formulations manufacturing. Derren Healthcare, a research-oriented company specializing in pharmaceutical products, has shown significant growth with its turnover increasing from INR 70.24 lacs in 2022-23 to INR 858.82 lacs in 2024-25. This strategic move is expected to enhance Genpharmasec's capabilities in the pharmaceutical sector.
Industry Peers
Redington
MMTC
MSTC
Ravindra Energy
Vintage Coffee & Beverages
BN Agrochem
Creative Newtech
TCC Concept
Elitecon International
Pervasive Commodities
394.80
(+0.71%)
61.33
(-1.45%)
741.25
(+0.50%)
152.76
(-1.50%)
175.80
(-0.64%)
204.94
(-3.33%)
1,117.00
(+2.83%)
55.68
(+3.84%)
8.15
(+4.49%)
9.42
(0.0%)
we are part of Raise Financial Services
built with love
for indians who love to invest & trade
Market Community
Follow us on
